Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.42 |
| ▸ | RARG | P13631 | 12/20 | 0.42 |
| ▸ | RXRB | P28702 | 8/20 | 0.42 |
| ▸ | RXRG | P48443 | 8/20 | 0.42 |
| ▸ | RARA | P10276 | 6/20 | 0.42 |
| ▸ | RARB | P10826 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 15/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303240 | 0.93 | RXRA (0.47) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6294277 | 0.92 | PPARG (0.34) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6281391 | 0.88 | RXRA (0.55) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6300016 | 0.88 | RXRA (0.43) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6293499 | 0.85 | RXRA (0.38) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6275501 | 0.84 | RXRA (0.58) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6299184 | 0.84 | PPARG (0.34) | PPARGPPARA | |
| SCHEMBL6305004 | 0.82 | RXRA (0.41) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6278794 | 0.82 | RXRA (0.43) | RXRARARGRXRBRXRGRARA | |
| SCHEMBL6304407 | 0.81 | RXRA (0.48) | RXRARARGRXRBRXRGRARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | RECORDATI IRELAND LTD. (IE) | 2005-07-28 | — | — | US | disclosed |
| WO-2005042509-A1 | 7-`(7-ALKOXY)-CHROM-3-EN-6-YL!-HEPTATRIENOIC ACID AND 7-`(3ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL!-HEPTATRIENOIC ACID DERIVATIVES MODULATORS | ALLERGAN, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | ALLERGAN, INC. | 2005-05-05 | — | — | US | disclosed |
| US-6887896-B1 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096380-A1 | 7-[(7-ALKOXY)-CHROM-3-EN-6-YL]-HEPTATRIENOIC ACID AND 7-[(3-ALKOXY)-5,6-DIHYDRONAPHTHALEN-2-YL]-HEPTATRIENOIC ACID DERIVATIVES HAVING SERUM GLUCOSE REDUCING ACTIVITY | TPO, THRA, FABP6 | RXRA 19/4885RARG 144/4885RXRB 33/4885 |
| US-20050165025-A1 | Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists | HTR1B, HTR1A, HTR2B | RXRA 2652/4885RARG 3088/4885RXRB 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.